MBX 700Alternative Names: MBX-700; SCH 900942
Latest Information Update: 19 Apr 2016
At a glance
- Originator Merck & Co
- Developer Microbiotix
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hepatitis C
Most Recent Events
- 02 Jan 2013 Phase-I clinical trials in Hepatitis C in USA (unspecified)